

09 Nov 2020 |

Quick Listen: Scrip's Five Must-Know Things

by **Ian Haydock**

Take a brief audio tour around the main biopharma industry events of the past week, as brought to you by *Scrip's* global team, in this podcast version of Five Must-Know Things.

Join us in our regular podcast on major industry events in this audio version of *Scrip's* Five Must-Know Things, this time for the business week ended 6 November 2020.

No surprises that the US presidential election features this week, along with a major oncology acquisition, use of AI in the hunt for COVID drugs, progress in atopic dermatitis, and the opportunity for pharma to rebuild its reputation amid the pandemic.

[Click here to explore this interactive content online](#) ✎

These and other Informa Pharma Intelligence podcasts are available on SoundCloud, Apple Podcasts and TuneIn, and also via Alexa smart speakers.

Articles mentioned in this episode:

(Also see "[President ?????: What US Election Uncertainty Means For Biopharma](#)" - Scrip, 4 Nov, 2020.)

(Also see "[Sanofi Bids €308m To Buy Kiadis](#)" - Scrip, 2 Nov, 2020.)

(Also see "[AI Can Find Many Drugs To Repurpose For COVID-19, But Real-World Results Mixed](#)" - Scrip, 4 Nov, 2020.)

(Also see "[Positive Atopic Dermatitis Data On Lilly's Newly-Approved Olumiant](#)" - Scrip, 2 Nov,

2020.)

(Also see "[Can Pharma Rebuild Its Reputation? COVID-19 Means A Big Responsibility, And Opportunity](#)" - Scrip, 30 Oct, 2020.)